Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Olema Pharmaceuticals Inc

OLMA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$10.63

▲ +1.14%

Market Cap $930.10M · Vol 342.40K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$930.10M

Small Cap

Div Yield

N/A

EPS Growth

-26.74%

YoY

RSI (14)

36.03

Momentum

Beta

1.96

vs Market

52W High

$36.19

70.63% below

52W Low

$5.30

100.57% above

Volume

342.40K

Avg 388.01K

P/B

4.25

Price-to-book

ROE

-36.61%

Return on equity

Free Float

97.63%

Public shares

Shariah Compliance8 STANDARDS

✗ Olema Pharmaceuticals Inc (OLMA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OLMA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-11.78%

-10.30%

-23.08%

-52.94%

YTD

-57.48%

+102.09%

-1.67%

-60.34%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-162,451,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-36.61%
ROA · ROIC	-33.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	4.25
P/FCF	N/A
EPS Growth	-26.74%
Outstanding Shares	87.50M

Technical Indicators

50-Day SMA	$11.22
200-Day SMA	$17.57
RSI (14)	36.03
Beta	1.96
52-Week High	$36.19
52-Week Low	$5.30

Volume Today	342.40K
Avg Daily Volume (30D)	388.01K
Relative Volume	0.88x
Volatility (10D)	72.42
Volatility (30D)	55.10
Free Float	97.63%

Analyst Consensus

BUY

Current Price $10.63

Mean Target $38.56

52W Low$5.30 52W High$36.19

Current

Target

$5.30 $36.19

Current Analyst target

+262.71% upside potential · 11 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00T5JMRV1

ISINUS68062P1066

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a novel, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Its second product candidate in clinical development, called OP-3136, is a novel, orally available small molecule that potently and selectively inhibits KAT6, an epigenetic target that is dysregulated in breast and other cancers.